EGFR-mutated advanced NSCLC cases treated with osimertinib + CT exhibited PFS significantly better than that of cases treated with aumolertinib (HR, 0.61, 95% CI, 0.40–0.93), furmonertinib (HR, 0.64, 95% CI, 0.41–0.98), lazertinib (HR, 0.64, 95% CI, 0.41–0.98), osimertinib (HR, 0.62, 95% CI, 0.48–0.80), osimertinib + bevacizumab (HR, 0.72, 95% CI, 0.51–1.00.51.00), befotertinib (HR, 0.57, 95% CI, 0.36–0.90), and zorifertinib (HR, 0.61, 95% CI, 0.39–0.93). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.